Pharma giant Merck (NYSE: MRK )
has been a little more active than normal lately, with most of its
activities pointing toward better value creation for its shareholders.
In addition to strong phase 2 hepatitis C data that vaults the company
back into serious competition, Merck was the first to file for approval
for its PD-1 drug, putting it in the lead to be first-to-market with
this next generation of oncology immunotherapies.
Merck also recently reported earnings, updated investors on its
R&D and strategic priorities, and finalized the sale of its consumer
health business to Bayer (NASDAQOTH: BAYRY )
. All of this activated hasn't radically changed the company's earnings
prospects, though it does free up significant capital that can be
returned to shareholders or invested back into the business.
Read the full article at The Motley Fool:
Why Merck's Bayer Deal Makes Sense
No comments:
Post a Comment